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Hepatocellular carcinoma (HCC), one of the most
common cancers worldwide, is often diagnosed at an
advanced stage when most potentially curative therapies
such as resection, transplantation or percutaneous and
transarterial interventions are of limited efﬁcacy. The fact
that HCC is resistant to conventional chemotherapy, and
is rarely amenable to radiotherapy, leaves this disease
with no effective therapeutic options and a very poor
prognosis. Therefore, the development of more effective
therapeutic tools and strategies is much needed. HCCs are
phenotypically and genetically heterogeneous tumors that
commonly emerge on a background of chronic liver
disease. However, in spite of this heterogeneity recent
insights into the biology of HCC suggest that certain
signaling pathways and molecular alterations are likely to
play esscntial roles in HCC development by promoting
cell growth and survival. The identiﬁcation of such
mechanisms may open new avenues for the prevention
and treatment of HCC through the development of
targeted therapies. In this review we will describe the
new potential therapeutic targets and clinical develop-
ments that have emerged from progress in the knowledge
of HCC biology, In addition, recent advances in gene
therapy and combined cell and gene therapy, together with
new radiotherapy techniques and immunotherapy in
patients with HCC will be discussed.
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Introduction
Hepatocellular carcinoma is the ﬁfth most common
cancer worldwide and the most common form of liver
cancer, being responsible for 80% of the primary
malignant liver tumors in adults. The 5-year relative
survival rate is about 7% and causes more than 600 000
deaths annually worldwide (Bosch et al., 2004). The
disease is most prevalent in Eastern and Southeastern
Asia, and Middle Africa, with more than half of the
patients being reported from China.
Even in developed countries, potentially curative
therapies are offered to only one in every four patients
coming to highly committed centers (Sangro et al., 1993;
Llovet et al., 1999). Tumor size, hepatic functional
reserve or portal hypertension restricts indication of
surgical or percutaneous ablation, and the success is
laden with a high recurrence rate. Transplantation is not
applicable universally and shortage of organ donation
limits its indication to patients with very early tumors.
For patients bearing non-ablatable tumors, transarterial
embolization may be used as a palliative therapy but
mostly for those asymptomatic patients with good liver
function and a patent portal vein. Hepatocellular
carcinoma (HCC) is a type of tumor highly resistant
to available chemotherapeutic agents, administered
either alone or in combination (Llovet et al., 2003). In
addition, conventional antineoplastic drugs are typically
non-selective cytotoxic molecules with signiﬁcant sys-
temic untoward effects. Thus, in many cases no effective
therapy at all can be offered to patients with HCC. In
this review, we will refer to new potential approaches to
treat HCC. We will focus on (a) targeted therapies that
have emerged from progress in the knowledge of HCC
biology and (b) recent advances in gene therapy and
combined cell and gene therapy. We will also make a
brief reference to new radiotherapy techniques and to
the role of immunotherapy in patients with HCC.
Biological therapy
Advances in the understanding of tumor biology are
opening new paths to treat cancer (Figure 1). These
novel therapeutics are slowly changing the prognosis of
patients suffering from certain malignant tumors and
this may also be the case for patients with invasive or
metastatic HCC in the near future.
Potential targets for therapeutic intervention
Hepatocarcinogenesis is a multistep process, slowly
unfolding on a background of chronic liver disease
including chronic hepatitis and cirrhosis, which are
regarded as preneoplastic stages (Coleman, 2003;
Bre´chot, 2004; Liang and Heller, 2004). Chronic
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hepatitis is a prolonged inﬂammatory process, with
inﬂammatory cells inﬁltrating the liver parenchyma and
triggering hepatocyte death. Persistent hepatocyte cell
death is followed by a regenerative response in which
viable hepatocytes are stimulated to proliferate in an
attempt to restore the loss of hepatic parenchyma
(Coleman, 2003; Taub, 2004). Proliferation of the stem
cell compartment of the liver is also observed in
experimental models of liver injury and carcinogenesis,
and in various conditions of acute and chronic liver
damage in humans (Libbrecht and Roskams, 2002; Sell,
2002). These stem cells, also called oval cells, possess an
extensive capacity for self-renewal, and upon tissue
injury expand in number and differentiate towards the
biliary and hepatocytic lineages (Libbrecht and Ros-
kams, 2002). Progression to liver cirrhosis is marked by
disruption of liver architecture and, in some cases,
aggregates of phenotipically altered hepatocytes emerge
within regenerative nodules, being these cells considered
as precursors of dysplastic nodules (Kojiro and Ros-
kams, 2005). The presence of dysplastic hepatocytes in
cirrhotic livers has been correlated with enhanced risk
for HCC development (Coleman, 2003), and it has been
suggested that many HCCs occurring in cirrhotic liver
develop form dysplastic nodules in a multistep fashion
(Kojiro and Roskams, 2005). Interestingly, the expres-
sion of markers of liver stem cells has been found in a
considerable proportion of human HCCs, suggesting the
possibility that human stem cells can give rise to HCC
(Libbrecht and Roskams, 2002). It has been recently
demonstrated that in solid tumors only a small
proportion of cancer cells retain the ability to form
new tumors (Al-Hajj and Clarke, 2004; Clarke, 2005;
Dean et al., 2005). The existence of a tumor stem cell
compartment in HCC, similar to that found in other
solid tumors, could have strong implications for the
treatment of liver cancer. The identiﬁcation of the
speciﬁc pathways involved in malignant stem cell
survival and proliferation can provide new opportunities
for targeted therapies.
Current evidences indicate that the precancerous liver
and the early stages in HCC development are character-
ized by certain common traits governed by both
epigenetic and genetic mechanisms (Thorgeirsson and
Grisham, 2002; Coleman, 2003). These common fea-
tures include the progressive hepatocyte dedifferentia-
tion due to impaired liver-speciﬁc gene expression (Avila
et al., 2000; Okabe et al., 2001; Berasain et al., 2003),
and the alteration of numerous signaling pathways
leading to autonomous and disregulated cell prolifera-
tion and resistance to cell death (Rust and Gores, 2000;
Okabe et al., 2001; Feitelson et al., 2002; Thorgeirsson
Figure 1 Relevant pathways in hepatocellular carcinoma (HCC) biology. Asterisks indicate potential targets (see main text for
details). ADAM: a disintegrin and metalloproteinase; APC: adenomatous Polyposis Coli; COX2: cyclooxygenase 2; EC: endothelial
cell; ECM: extracellular matrix; ERK: extracellular signal-regulated kinase; FAK: focal adhesion kinase; GF: growth factor; GSK3b:
glycogen synthase kinase 3-beta; HIF-1a: hypoxia-inducible factor 1-alpha; IGF-II: insulin-like growth factor II; IGF-IR: insulin-like
growth factor I receptor; ILK: integrin-linked kinase; MEK: mitogen-activated protein kinase kinase (extracellular signal-regulated
kinase kinase); mTOR: mammalian target of rapamycin; NF-kB: nuclear factor-kappa B; ODC: ornithine decarboxylase; PGs:
prostaglandins; PI3K: phosphatidylinositol 3-kinase; pRb: phospho-retinoblastoma (Rb); PTEN: phosphatase and tensin homolog;
ROS: reactive oxygen species; RTK: receptor tyrosine kinase; STAT: signal transducer and activator of transcription; TERT:
telomerase reverse transcriptase; TGF-b: transforming growth factor-beta; VEGF: vascular endothelial growth factor. m and .
indicate enhanced or reduced gene expression in HCC as compared to normal liver.
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and Grisham, 2002; Lee and Thorgeirsson, 2004; Arsura
and Cavin, 2005; Kim et al., 2005; Roberts and
Gores, 2005). Hierarchical clustering of human HCC
samples based on gene expression patterns identiﬁed
two subclasses of HCC with strong association with
the survival of the patients, and noteworthy the
expression of cell proliferation markers and antiapop-
totic genes was signiﬁcantly higher in the group of
patients with poorer prognosis (Lee and Thorgeirsson,
2004, 2005).
Inactivation of the tumor-suppressor genes p53 and
the retinoblastoma gene (Rb) through different mole-
cular mechanisms has been observed in a signiﬁcant
percentage of HCCs of viral or alcoholic etiology, and in
preneoplastic conditions such as chronic hepatitis and
cirrhosis (Buendia, 2000; Feitelson et al., 2002; Cole-
man, 2003; Edamoto et al., 2003). A higher percentage
of p53 genetic alterations are observed in advanced
stages of HCC, suggesting that these abnormalities are
associated with more advanced disease (Kim et al.,
2005). The product of the p53 gene is involved in many
essential functions, including the regulation of DNA
replication and repair, and the induction of apoptosis.
Its activity is regulated by p14ARF, a protein that
indirectly stabilizes p53 by preventing mdm-2-dependent
p53 ubiquitination and degradation (Zhang et al., 1998).
Interestingly, p14ARF promoter hypermethylation and
reduced p14ARF expression are also frequently detected
in HCC, further contributing to the impairment of the
p53 tumor-suppressor pathway (Feitelson et al., 2002;
Edamoto et al., 2003). Likewise, deletions of the Rb
gene, and Rb promoter hypermethylation leading to loss
of expression are frequent in the cirrhotic liver and HCC
(Feitelson et al., 2002; Coleman, 2003; Kim et al., 2005).
The Rb tumor-suppressor normally inhibits cell cycle
progression through its binding to the transcription
factor E2F1. Phosphorylation of Rb by the cyclin-
dependent kinase 4(CDK4)/cyclin D1 complex results in
the release of E2F1, which in turn activates the
expression of genes involved in the G1–S transition. In
addition to direct Rb gene alterations, impairment in the
expression of the CDK4 inhibitor p16INK4 can also lead
to Rb disregulation in hepatocarcinogenesis (Feitelson
et al., 2002; Edamoto et al., 2003). It is important to
mention that alterations in the endogenous tumor-
suppressor networks is a main contributor to the
resistance of HCC to classical cancer therapies, in part
because the activity of most conventional chemother-
apeutic agents depends to a great extent on the same
innate pro-apoptotic pathways that are disabled in HCC
(Chan and Lung, 2004; Lowe et al., 2004; Mu¨ller et al.,
2005).
Interestingly, gankyrin, a gene that is consistently
overexpressed in human HCC, has been identiﬁed as a
novel negative regulator of both p53 and Rb levels
(Lozano and Zambetti, 2005). Gankyrin facilitates the
phosphorylation and degradation of Rb through differ-
ent pathways (Higashitsuji et al., 2000) and enhances the
ability of the ubiquitin ligase mdm-2 to recruit p53 to
the proteasome for its degradation (Higashitsuji et al.,
2005). Downregulation of gankyrin by RNA interfer-
ence increased p53 protein levels and activity, and
promoted apoptosis (Higashitsuji et al., 2005). These
actions make gankyrin a potential contributor to HCC
development, and suggest that blocking its activity may
prove a valuable targeted therapy for HCC.
Gankyrin was originally identiﬁed as a component of
the regulatory subunit of the proteasome (Lozano and
Zambetti, 2005). The ubiquitin-proteasome pathway is
an essential regulator of cellular processes such as the
cell cycle, signal transduction pathways and apoptosis.
Given that both, tumor-suppressor proteins and onco-
proteins, are targets of ubiquitination, initially it was
not conceptually obvious that proteasome inhibition
could result in the selective killing of cancer cells (Mani
and Gelmann, 2005). However, accumulating evidences
show that proteasome inhibitors can induce apoptosis of
cancer cells and reduce tumor growth in mouse
xenograft models (Adams, 2004). Furthermore, protea-
some inhibitors such as bortezomib also sensitize tumor
cells to chemotherapeutic agents, or to the activation of
death signaling pathways as recently observed in human
HCC cells (Ganten et al., 2005). Indeed, pretreatment
with bortezomib sensitized HCC cells to apoptosis
induced by the tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL), while primary hu-
man hepatocytes were spared from this effect (Ganten
et al., 2005).
Overexpression of cell cycle regulatory genes such as
cyclins D1, E and A, and enhanced activity of CDK4
have been widely documented in human HCC and in the
cirrhotic liver (Deane et al., 2001; Coleman, 2003;
Masaki et al., 2003; Huynh et al., 2004; Osada et al.,
2005). Similarly, transcription factors that exert positive
effects on cell proliferation, such as c-myc, are over-
expressed in human HCC (Coleman, 2003). Another
example is the Foxm 1b gene, a transcription factor
markedly induced at the G1/S transition during liver
regeneration that is also upregulated in human HCC
(Okabe et al., 2001; Kalinichenko et al., 2004). A
remarkable example of the potential of manipulating a
single oncogenic pathway for HCC development has
been recently provided (Shachaf et al., 2004). Using
transgenic mice that conditionally expressed the c-myc
oncogene in the liver in an inducible manner, these
authors found that switching on c-myc expression
resulted in the development of HCC, however subse-
quent c-myc inactivation induced a sustained regression
of invasive liver cancer, with tumor cells rapidly
differentiating into apparently normal hepatocytes and
biliary cells. Together, these observations lend further
support to the hypothesis that continuous stimulation
through mitogenic and survival signaling pathways is
central for the development of HCC from the early
stages, and that targeting one of these key pathways can
reverse the neoplastic phenotype. Furthermore, most of
these signaling and regulatory mechanisms are modiﬁed
by infection with hepatitis B or C viruses, which are
regarded as major etiologic agents of HCC (Feitelson,
2005). Among the most critical cellular signaling path-
ways for hepatocarcinogenesis are the Wnt/b-catenin
pathway and receptor tyrosine kinase (TK)-activated
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pathways, including ras/raf/MEK/ERK, PI3K/Akt/
mammalian target of rapamycin (mTOR), nuclear
factor-kappa B (NF-kB) and JAK/STAT (Masaki
et al., 1998; Harada et al., 1999; Giles et al., 2003;
Hu et al., 2003; Hwang et al., 2004; Pikarski et al.,
2004; Sahin et al., 2004; Arsura and Cavin, 2005)
(Figure 1).
Abnormal regulation of b-catenin is an early event in
hepatocarcinogenesis. b-Catenin is a key intracellular
effector in the Wnt signaling pathway, and also
participates in homotypic cell-cell interactions through
its association with E-cadherin (Giles et al., 2003; Harris
and Peifer, 2005). Wnts are a large family of secreted
glycoproteins that signal through binding to members of
the frizzled (Fzd) family of seven-span transmembrane
receptors (Giles et al., 2003). In quiescent epithelial cells
b-catenin is found in a submembranous location
complexed to glycogen synthase kinase 3b (GSK3b),
axin and the tumor-suppressor adenomatous polyposis
coli (APC). GSK3b is active in unstimulated cells and
mediates the phosphorylation of b-catenin in key serine
and threonine residues that mark b-catenin for ubiqui-
tination and proteasomal degradation (Aberle et al.,
1997; Nelson and Nusse, 2004). In the canonical Wnt
pathway, Wnt ligands bind the Fz receptors and activate
the downstream effector dishevelled (Dvl), which in turn
prevents the phospohorylation of b-catenin by GSK3b
and its subsequent degradation. Accumulation of b-
catenin in the cytoplasm leads to its translocation to the
cell nucleus, where it binds the transcription factors Tcf/
Lef and acts as a coactivator to stimulate the transcrip-
tion of many genes involved in cell proliferation, such as
c-myc, c-jun and cyclin D1, angiogenesis, anti-apoptosis
and in the formation of extracellular matrix (ECM)
(Buendia, 2000; Calvisi et al., 2001). About 50–70%
of all HCC examined presented accumulated levels of
b-catenin in the cytoplasm and nucleus (Wong et al.,
2001). Mutations in b-catenin can lead to its stabiliza-
tion and intracellular accumulation, mimicking Wnt
stimulation. These mutations occur in almost all stages
of HCC development, suggesting that impairment of
b-catenin turnover can contribute to many different
aspects of the process of liver malignization, including
the development of ﬁbrosis and cirrhosis that precede
tumor formation (Feitelson et al., 2002; Edamoto et al.,
2003).
Another recently recognized mechanism leading to
enhanced b-catenin accumulation in the absence of b-
catenin mutations involves the overexpression of the
Fzd type 7 receptor, which is already observed in
dysplastic hepatocytes prior to HCC development
(Merle et al., 2004). These receptors may thus constitute
another target for HCC prevention. Alternatively, b-
catenin accumulation in HCC cells has been correlated
with impaired E-cadherin gene expression, due to LOH
at the E-cadherin locus or epigenetic mechanisms such
as promoter hypermethylation or binding of transcrip-
tional repressors (Matsumura et al., 2001). Loss or
reduced expression of E-cadherin is likely to result in
redistribution of b-catenin to the cell nucleus, and is also
thought to have important consequences for hepatocel-
lular dedifferentiation, angiogenesis, tumor invasiveness
and metastasis (Calvisi et al., 2004).
Interestingly, besides the aforementioned implications
of the Wnt/b-catenin pathway in well-established
tumorigenic events, Wnts are also involved in the
regenerative response of the liver and in the maintenance
of the stem cell pool (Monga et al., 2001; Dean et al.,
2005; Reya and Clevers, 2005). These notions suggest
that targeting the Wnt/b-catenin pathway may also be a
strategy to quell the tumor stem cell compartment.
Although still in their early development, different
strategies are being tested to interfere with this pathway.
For example, blockade of Wnts with monoclonal
antibodies (mAbs) (You et al., 2004; He et al., 2005),
and small molecules that interfere with the interaction of
b-catenin with Tcf or other transcriptional regulators
such as the CREB-binding protein CBP (Lepourcelet
et al., 2004; Emami et al., 2004). Additionally, due to the
extensive crosstalk between signaling pathways acti-
vated in chronic liver injury and HCC, the activity of the
Wnt/b-catenin axis can be interfered through the
inhibition of other targets such as the enzyme cycloox-
ygenase (COX) and, as discussed below, the ras-/raf-/
MEK-/ERK- and PI3K-signaling cascades (Ding et al.,
2005; Beurel et al., 2005; Street et al., 2005). Wnt/b-
catenin cascade is repressed by inhibitors of the
inducible isoenzyme COX2 (Giles et al., 2003; Dihlmann
and von Knebel Doeberitz, 2005), a type of drugs that
hold promise for chemoprevention of HCC (Hu, 2002).
Besides the Wnt/b-catenin axis, the ras/raf/MEK/
ERK pathway is one of the most critical signaling
cascades for liver tumorigenesis (Chung et al., 2000;
Coleman, 2003; Hwang et al., 2004; Wiessenauer et al.,
2004; Osada et al., 2005; Schiffer et al., 2005). This
pathway is central in cell growth and survival, transdu-
cing extracellular signals from ligand-bound TK recep-
tors such as epidermal growth factor receptor (EGFR),
vascular endothelial growth factor receptor (VEGFR),
insulin-like growth factor receptor (IGFR), platelet-
derived growth factor receptor (PDGFR), the stem cell
growth factor receptor c-kit, and the hepatocyte growth
factor receptor (MET), to the cell nucleus through a
series of speciﬁc phosphorylation events that start with
the activation of Ras (Alexia et al., 2004; Sridhar et al.,
2005). Activated Ras turns on a family of serine
threonine kinases known as Raf kinases that phosphor-
ylate and activate MEK1/2, which in turn activates
ERK1/2. Subsequently, ERK1/2 kinases phosphorylate
a wide range of downstream effectors involved in many
aspects of tumorigenesis, ranging from cell immortaliza-
tion by telomerase induction to apoptosis resistance,
ECM remodeling, cellular motility, angiogenesis and
drug resistance (Wiessenauer et al., 2004; Sridhar et al.,
2005).
As just mentioned, activation of the ras/raf/MEK/
ERK can be achieved by ligand binding to different
membrane receptors with TK activity, including the
EGFR. The adult hepatocyte is the cell type in the
organism where the EGFR is expressed at the highest
levels, and it is thought to play a central role in liver
regeneration after partial hepatectomy and tissue injury
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(Taub, 2004). Although this receptor is not commonly
overexpressed in HCC cells, its continuous activation by
ligands such as transforming growth factor-a (TGF-a),
heparin-binding EGF (HB-EGF) or amphiregulin (AR),
which are upregulated from the early stages of
hepatocarcinogenesis, can be of signiﬁcance for HCC
development (Inui et al., 1994; Chung et al., 2000;
Berasain et al., 2005a, b; Schiffer et al., 2005). These
EGFR ligands are produced as transmembrane pre-
cursors, and need to be proteolitically released from the
cell surface to signal in an autocrine or paracrine fashion
(Yarden, 2001). Shedding of EGFR ligands is carried
out by metalloproteinases of the ADAM family, which
are also transmembrane proteins (Blobel, 2005). Inter-
estingly, the expression of tumor necrosis factor-a-
converting enzyme (TACE)/ADAM17, the metallopro-
teinase that cleaves the AR precursor, is upregulated in
human HCC together with that of its target gene AR
(Ding et al., 2004; Berasain et al., manuscript in
preparation). Moreover, we have recently found that
TACE/ADAM17 gene expression is already elevated in
the cirrhotic liver (Berasain et al., manuscript in
preparation), which further supports the early involve-
ment of the EFGR system in the process of hepato-
carcinogenesis. Among the different approaches
undertaken to inhibit EGFR function are neutralizing
mAbs to the EGFR, and small molecule inhibitors of
the EGFR TK activity (Mosesson and Yarden, 2004;
Baselga and Arteaga, 2005).
Anti-EGFR antibodies such as cetuximab, panitumu-
mab or ABX-EGF bind to the extracellular ligand-
binding domain of EGFR and completely prevent
ligand binding this receptor. Small molecule EGFR
inhibitors are usually quinazoline derivatives that
compete with ATP binding to the TK domain of the
receptor. These molecules belong to two categories:
reversible inhibitors such as geﬁtinib and erlotinib, and
irreversible inhibitors that covalently bind to cysteine
residues in the ATP-binding site of EGFR, such as
lapatinib, CI-1033 and EKB-569 (Baselga and Arteaga,
2005; Camp et al., 2005). The inhibitory activity of
geﬁtinib and erlotinib on human HCC cell growth in
culture has been recently demonstrated. These com-
pounds induced cell cycle arrest and apoptosis, and
erlotinib enhanced chemosensitivity towards cytostatics
(Ho¨pfner et al., 2004; Huether et al., 2005). In addition,
in vivo studies have shown that geﬁtinib displays
antitumoral effects in a rat model of chemically induced
liver cirrhosis and HCC (Schiffer et al., 2005).
In spite of the promising results, previous experiences
with anti-EGFR-targeted therapies in other types of
tumors have shown that many patients show a very poor
response or progressively develop resistance to the
therapy (Camp et al., 2005). Various mechanisms
account for such resistance, and some of them are
present in HCC cells. For instance, alternative TK
receptors can activate the same critical downstream
promitogenic and antiapoptotic mechanisms triggered
by EGFR, and thus compensate for EGFR blockade.
This could be the case of the IGFR, its expression and
that of its ligand IGFII is signiﬁcantly upregulated in
human cirrhotic liver and HCC (Alexia et al., 2004).
Activation of the IGFR has been shown to stimulate the
Ras/Raf/MEK/ERK, PI3K/Akt/mTOR and b-catenin
pathways in HCC cells, and is considered to participate
in HCC development through an autocrine mechanism
(Desbois-Mouthon et al., 2001; Alexia et al., 2004).
Therefore, targeting the IGFII/IGFR system can be also
regarded as an antineoplastic strategy for liver cancer by
itself. Inhibition of IGFR signiﬁcantly reduces resis-
tance to anti-EGFR-targeted therapies, as has been
observed in human breast carcinoma cells simulta-
neously treated with the IGFR inhibitor AG1024 and
geﬁtinib (Camirand et al., 2005), suggesting that similar
combinations of targeted therapies may be effective in
HCC.
Previous observations in non-small-cell lung cancer
(NSCLC) patients identiﬁed somatic mutations in exons
18–21 of the EGFR that strongly correlated with robust
clinical responses to geﬁtinib treatment (Baselga and
Arteaga, 2005). However, in a recent report that
examined 89 human HCC samples no such mutations
were found, suggesting that human liver tumors are
unlikely to show a good response to geﬁtinib (Su et al.,
2005). Additionally, enhanced expression of EGFR
ligands can also induce tumor cell resistance to EGFR
inhibitors. This situation has been also observed in
NSCLC cells, in which the overexpression of AR
signiﬁcantly conditions the sensitivity to geﬁtinib
(Kakiuchi et al., 2004). Furthermore, increases in the
circulating levels of AR and TGF-a have been proposed
as predictors of poor response to geﬁtinib in patients
with NSCLC (Ishikawa et al., 2005). These observations
suggest that targeting EGFR ligands could be of value
in overcoming resistance towards EGFR inhibitory
molecules.
The ligand-independent constitutive activation of
signaling pathways downstream of receptor TKs, such
as the Ras/Raf/MEK/ERK pathway, can play an
important role in tumor development, and is considered
as another mechanism of resistance to receptor-targeted
therapies (Camp et al., 2005). A variety of agents have
been developed to interfere with these pathways at
different levels. Overexpression of Ras proteins is
frequently observed in HCC and preneoplastic liver
(Coleman, 2003). In order to be competent for signal
transduction, these guanine nucleotide-binding proteins
need to be post-translationally modiﬁed by the incor-
poration of prenyl moieties (farnesyl and geranylgeranyl
groups). Based on this, different inhibitors of the
enzyme farnesyl transferase have been developed,
however, clinical experience in solid tumors has shown
limited efﬁcay for these agents when used as single drugs
(Graaf et al., 2004). Nevertheless, recent experimental
evidences with ABT-100, a novel highly potent farnesyl-
transferase inhibitor, showed clear chemopreventive
effects in chemically induced HCC in rats (Carloni
et al., 2005). Interestinlgy, PI3K/Akt inhibition was
also observed in response to ABT-100 treatment
(Carloni et al., 2005). An alternative approach to
prevent prenylation of Ras proteins is to interfere with
the activity of 3-hydroxy-3-methylglutaryl coenzyme-A
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reductase (HMG-CoAR), the rate-limiting enzyme in
the mevalonate pathway that leads to the production of
isoprenoids. Targeting of HMG-CoAR can be achieved
with statins, a group of drugs widely used to treat
patients with hypercholesterolemia. It has been recently
reported that treatment of human HCC cells with statins
blocks ERK1/2 activation and induces cell cycle arrest
and apoptosis (Sutter et al., 2005). Dowstream of Ras,
one of the most promising agents is the orally available
Raf kinase inhibitor BAY 43-9006 (sorafenib), which
has shown encouraging effects in several xenograft
models of tumors dependent on signaling through the
Ras/Raf/MEK/ERK pathway (Sridhar et al., 2005;
Thompson and Lyons, 2005). Although originally
developed as a Raf kinase inhibitor, it was subsequently
appreciated that BAY 43-9006 was able to inhibit other
kinases relevant to the carcinogenic and angiogenic
processes such as VEGFR-2, VEGFR-3, PDGFR-b,
c-kit and p38a (Sridhar et al., 2005). MEK is the kinase
dowstream of Raf, and is also an atractive target for
HCC (Wiessenauer et al., 2004; Osada et al., 2005;
LoRusso et al., 2005). Preclinical studies have proved
the potential of MEK inhibition in suppressing hepato-
ma cell proliferation and tumorigenicity (Wiessenauer
et al., 2004).
Activation of the PI3K/Akt/mTOR pathway is
believed to play a key role in tumor development (Osaki
et al., 2004). Besides stimulating cellular proliferation,
these kinases promote cell survival through the coordi-
nate regulation of apoptosis and cellular metabolism
(Amaravadi and Thompson, 2005). PI3K is directly
associated with many cell surface growth factor
receptors, which upon ligand binding trigger the
activation of this lipid kinase and generate the second
messenger phosphatidylinositol 3,4,5-triphosphate
(PIP3). Phosphatidylinositol 3,4,5-triphosphate in turn
recruits and contributes to activate Akt, a serine/
threonine kinase that regulates the apoptotic machinery
at multiple levels, including the phosphorylation and
inactivation of pro-apoptotic proteins such as Bad and
caspase-9, the induction of NF-kB-dependent survival
genes like Bcl-XL and the key metabolic regulator
mTOR (Vignot et al., 2005). An essential regulator of
this route is the PIP3 phosphatase PTEN, a ubiquitously
expressed tumor-suppressor gene frequently lost in
human HCC, and that upon targeted deletion in mouse
hepatocytes leads to the development of HCC (Hu et al.,
2003; Horie et al., 2004). Thus, constitutive activation of
this pathway in HCC can be due to enhanced stimula-
tion of receptor TKs, such as EGFR and IGFR, but
also to decreased PTEN expression. The latter condition
implies that liver tumors with impaired PTEN expres-
sion can be resistant to receptor TK-targeted therapies.
This has been already observed for breast cancer cells
with mutated PTEN, in which sensitivity to geﬁtinib
could be restored after adenoviral delivery of wild-type
PTEN (Bianco et al., 2003). Together these observations
make the inhibition of Akt activation an attractive
strategy for targeted HCC therapy. Upstream of Akt,
PI3K inhibitors such as wortmannin and LY294002
have shown some efﬁcacy in experimental models of
HCC (Nakanishi et al., 2002), but clinical development
has been precluded due to broad speciﬁcity kinase
inhibition, weak inhibitory activity and poor pharma-
cokinetics (Amaravadi and Thompson, 2005). The direct
inhibition of Akt has been also considered for the
treatment of solid tumors. The orally bioavailable
alkylphospholipid perifosine, an inhibitor of Akt
targeting to the cell membrane, is currently in phase II
trials after showing partial responses in earlier clinical
studies (Amaravadi and Thompson, 2005).
Downstream of Akt is mTOR, a serine/threonine
kinase that is probably one of the most promising
candidate targets within this pathway. Through a
complex mechanism PI3K/Akt mediates the activation
of mTOR, which in turn exerts profound effects on gene
expression by the regulation of the cell translational
machinery. The two main effectors of mTOR are the
eukaryotic initiation factor 4E-binding protein-1 (4E-
BP1), and the 40S ribosomal protein S6 kinase (p70s6k).
These proteins regulate the translation of many mRNAs
corresponding to genes involved in cell proliferation and
angiogenesis such as c-myc, cyclin D1, ornithine dec-
arboxylase, hypoxia-inducible factor 1-a, and indirectly
the expression of VEGF (Adjei and Hidalgo, 2005).
Rapamycin, a natural antibiotic, is a potent and speciﬁc
inhibitor of mTOR that prevents p70s6k and 4E-BP1
phosphorylation. In the clinical setting rapamycin is well
known as an immunosuppressive drug used to prevent
renal graft rejection (Vignot et al., 2005). Convincing
antineoplastic effects for rapamycin have been observed
in experimental models, and have prompted the devel-
opment of rapamycin analogues with more favourable
pharmaceutical properties as anticancer agents (Vignot
et al., 2005; Adjei and Hidalgo, 2005). Phase I and II
studies for the rapamycin analogues CCI-779, RAD001
and AP23573 have shown some activity in solid tumors,
and their use in combination with chemotherapy is being
explored (Adjei and Hidalgo, 2005). In this respect, it
has been recently reported that the phosphorylation of
mTOR and the expression of p70s6k is upregulated in a
signiﬁcant number of human HCCs (45% of cases), and
that rapamycin markedly inhibits the proliferation of
human HCC cell lines (Sahin et al., 2004). Although
mTOR inhibitors have not been tested yet in animal
models of HCC, these observations together with the
frequent loss of PTEN in human HCC, suggest a
potential use for these agents in liver cancer.
As previously mentioned, the expression of the proto-
oncogene c-myc can be activated by practically all the
signaling pathways activated during HCC development,
and is frequently observed in liver tumor samples. This
proto-oncogene in turn stimulates the expression of
many growth-related genes. Among them, telomerase is
believed to play an important role in HCC progression.
Its activity is upregulated in over 80% of human HCC
biopsies while normal liver tissues show undetectable or
very low telomerase activity (Satyanarayana et al.,
2004). Telomerase consists of two components, an
RNA (TERC) that serves as a template for the synthesis
of the telomere sequence, and a reverse transcriptase
(TERT). The main function of telomerase is the de novo
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synthesis of telomeres, structures that cap the chromo-
some ends protecting them from fusion and triggering
DNA-damage recognition (Satyanarayana et al., 2004).
Telomere shortening limits the growth of primary
human cells, and it has been proposed that repression
of telomerase is a tumor-suppressor mechanism. There-
fore, targeting telomerase activity may be exploited as a
novel therapy for HCC. Several classes of telomerase
inhibitors with different mechanisms of action have been
designed and evaluated (Dikmen et al., 2005). In a very
recent report, two thio-phosphoramidate oligonucleo-
tides that inhibit telomerase through targeting the
TERC component, GRN163 and its lipid-conjugated
derivative GRN163L, have been tested on human
hepatoma cells. These compounds inhibited HCC cell
growth in vitro and in the xenograft model, and did not
show any adverse effects (Djojosubroto et al., 2005).
GRN163L has been recently approved to enter phase
I/II clinical trials in chronic lymphocytic leukemia
(Djojosubroto et al., 2005).
Increasing evidences point to the constitutive
activation of the transcription factor NF-kB as one
early key event in hepatic oncogenesis (Arsura and
Cavin, 2005). In non-stimulated hepatocytes NF-kB is
retained in the cytoplasm by a group of inhibitory
factors known as inhibitor kappa B (IkB) proteins. In
response to a variety of stimuli, including viral infection,
pro-inﬂammatory cytokines and growth factors, IkB
proteins are phosphorylated by the IkB kinase (IKK)
complex and targeted for proteasomal degradation,
which allows the NF-kB constituents (there are ﬁve
NF-kB family members) to translocate to the cell
nucleus and activate gene transcription (Arsura and
Cavin, 2005; Luo et al., 2005). Nuclear factor-kappa B
induces the expression of many genes that inhibit both
apoptotic and necrotic cell death, representing a general
defense mechanism towards hepatocellular damage of
diverse etiology. However, its persistent activation
during preneoplastic stages can confer a survival
advantage to hepatocytes that have acquired oncogenic
mutations, thus favoring tumor promotion (Pikarski
et al., 2004). This may be one of the mechanisms linking
chronic inﬂammation and tumorigenesis. According to
these concepts NF-kB inhibitors would be useful in
HCC prevention and treatment. Speciﬁc IKK inhibitors
such as b-carbolin and quinazoline analogues are
currently under preclinical development (Arsura and
Cavin, 2005).
Angiogenesis is a crucial process for tumor progres-
sion, and is also intimately related to tumor invasion
and metastasis. The formation of new blood vessels is a
multistep process that involves not only the tumor cells,
but also the tumor matrix, stroma and vasculature. A
variety of factors stimulate the proliferation, survival,
migration and assembly of vascular endothelial cells into
new blood vessels that feed the tumor (Zacharoulis
et al., 2005). Among these factors, the previously
mentioned VEGF plays a predominant role, although
basic ﬁbroblast growth factor, PDGF, IGF, angiopoie-
tin-1 and interleukin (IL)-8 are also involved in the
neovascularization of tumors, including HCC (Eskens,
2004; Zacharoulis et al., 2005). Overexpression of
VEGF has been detected in HCC, and its upregulation
can be attributed to different effectors such as the
hypoxic tumor environment, or the activation of EGFR
and COX2 signaling (Ryan and Wedge, 2005).
In principle, targeted inhibition of angiogenesis can be
achieved at different levels. These include the neutraliza-
tion of growth factors with mAbs, the inhibition of the
dowstream signaling from TK receptors, and the
interference with the interaction between proliferating
endothelial cells and matrix components (Eskens, 2004;
Ryan and Wedge, 2005; Zacharoulis et al., 2005).
Bevacizumab, a humanized recombinant mAb to
VEGF, has jumped ﬁrst into the clinical setting but
many other small molecule VEGFR inhibitors are
currently being tested in combination with conventional
antineoplastics for the treatment of metastatic colorectal
cancer. Among them is PTK787, an orally available
VEGFR-1 and VEGFR-2 TK inhibitor that has shown
promising effects on HCC xenografts in nude mice (Liu
et al., 2005). Other compounds such as ZD6474 and CP-
547,632 are able to inhibit both VEGFR and EGFR TK
activity. These molecules can target tumor growth via
inhibition of VEGF-mediated angiogenesis and en-
dothelial cell survival, and through the direct inhibition
of tumor cell proliferation and survival. Hepatocellular
carcinoma treatment could beneﬁt from the use of these
agents, given the prominent role of the EGFR system in
this type of tumor.
Another approach proposed to limit tumor-associated
angiogenesis targets the interaction of the endothelial
cells with the ECM. This interaction is important in
mediating cell spreading and migration, and cell matrix
receptors such as the transmembrane endothelial cell
integrins anb3 and anb5 are thought to play a major role
(Stupack and Cheresh, 2004). The efﬁcacy of medi-522,
a humanized mAb targeting the integrin anb3 receptor,
and that of cilengitide, a small molecule inhibitor of
anb3 and anb5 integrins, is currently being tested in
clinical trials (Eskens, 2004).
Thalidomide is one of the few agents with antiangio-
genic potential that has been clinically tested against
HCC (Zacharoulis et al., 2005). Its mechanism of action
is not completely known, and may involve its ability to
interfere with anb3 and anb5 integrin receptors and to
modulate the inﬂammatory response, which also con-
tributes to neo-angiogenesis. The efﬁcacy of thalidomide
in human studies was limited to a few isolated responses,
mostly manifested as disease stabilization. A second-
generation thalidomide analog, lenalidomide, with much
more potent immunomodulatory and antiangiogenic
properties is currently being evaluated in patients with
solid tumors (Zacharoulis et al., 2005).
Given the essential role of angiogenesis for HCC
development, the identiﬁcation of novel molecules and
pathways to interfere with is a major issue. One of these
novel targets may be represented by the ephrin/eph
system. Ephrin ligands are membrane-anchored proteins
that bind and activate a large family of receptor with TK
activity, known as Eph receptors. The ephrin/eph
signaling system was known to be an important
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regulator of angiogenesis during development, however
more recently has been shown to participate also in
tumor neovascularization (Ogawa et al., 2000). Recent
experimental observations clearly demonstrated that
ephrin-B1, an ephrin family member speciﬁcally upre-
gulated in human HCCs, was able to stimulate the
proliferation of endothelial cells in vitro and to promote
tumor growth and in a xenograft model (Sawai et al.,
2003). This effect was mainly attributed to its ability to
initiate tumor angiogenesis, suggesting that the inhibi-
tion of ephrin-B1 function could be a novel approach to
quell HCC neovascularization.
An important event during later stages in the
development of epithelial tumors, including HCC,
involves the loss of cell-to-cell contacts and the
acquisition of a ﬁbroblastoid phenotype, referred to as
epithelial–mesenchymal transition (EMT) (Gotzmann
et al., 2001; Thiery, 2003; Thompson and Newgreen,
2005). Regarding tumor development, the relevance of
these changes resides on the fact that EMT appears to
participate in the metastatic process by enhancing the
migratory and invasive properties of transformed cells.
Moreover, EMT of liver cells can also result in enhanced
resistance to apoptotic signals, further contributing to
the neoplastic phenotype (Valde´s et al., 2002). There are
a number of molecular mechanisms and crosstalks
among signaling pathways in tumor-associated EMT.
As mentioned above, loss of cell–cell adhesion and
cytoeskeletal rearrangements are hallmarks of EMT.
The downregulation of the tumor-suppressor protein E-
cadherin, a prime determinant of epithelial cell struc-
ture, is central to the EMT process. As previously
indicated impaired E-cadherin expression is frequently
observed in HCC tissues (Calvisi et al., 2004).
The molecular mechanisms of E-cadherin down-
regulation are not completely known, a recent report
showed that in HBV-associated HCC E-cadherin
expression is silenced through the hypermethylation of
its promoter (Lee et al., 2005). Additionally, the
inactivation of GSK3B, frequently observed in HCC,
seems to be involved in the downregulation of
E-cadherin expression and in the activation of transcrip-
tion factors relevant to EMT such as Snail (Bachelder
et al., 2005). However, in E-cadherin silencing, and
in hepatocarcinogenesis-associated EMT as a whole,
TGF-b plays a predominant role (Gotzmann et al.,
2001). This cytokine is not detected in healthy adult
hepatocytes, however, its expression is signiﬁcantly
induced in HCC (Bedossa et al., 1995). While in normal
adult hepatocytes TGF-b displays growth-inhibitory
and pro-apoptotic properties, in liver tumor cells these
reponses are lost. The binding of TGF-b to its cell
surface receptors triggers intracellular signaling
mediated by the phosphorylated Smad proteins, among
which Smad3 seems to play a central role in the
regulation of EMT-related changes in gene expression
(Zavadil and Bo¨ttinger, 2005). Additionally, extensive
crosstalk exists between the TGF-b/Smad pathway and
other signaling cascades in the promotion of EMT. Of
special relevance is the cooperation with the Ras/Raf/
MEK/ERK and PI3K/Akt pathways previously
described, signaling cascades experimentally demon-
strated to induce and maintain EMT in liver cells
(Gotzmann et al., 2001; Lan et al., 2004; Fischer et al.,
2005; Zavadil and Bo¨ttinger, 2005). Recent studies have
identiﬁed the NF-kB signaling system as another key
modulator in TGF-b-induced EMT in mammary
epithelial cells, suggesting its likely implication in
HCC-associated EMT (Zavadil and Bo¨ttinger, 2005).
Taken together these observations suggest that the
pharmacologic inhibition of TGF-b signaling could be
relevant to prevent epithelial cell dedifferentiation and
tumor metastasis. The identiﬁcation of such inhibitors is
vigorously pursued, and some promising experimental
observations have been obtained with BIBU 3029, a
small molecule inhibitor of TGF-b TK activity that
prevents EMT in vitro (Eger et al., 2004). It would be
interesting to test such compounds in combination with
inhibitors of the signaling pathways that cooperate with
TGF-b in the EMT of transformed liver cells.
A key aspect of HCC biology is the interaction of the
transformed cell with the ECM. As described before,
HCC frequently develops on a ﬁbrotic environment, a
situation in which profound quantitative and qualitative
alterations of the ECM have occurred (Bissell, 2001).
Accumulating evidences indicate that these changes in
ECM could play a role in liver tumorigenesis. For
instance, it has been proposed that the extent of
cirrhosis and ﬁbrosis in HCC patients is a negative
predictor of survival (Lee et al., 1997), and that the de
novo expression of ECM constituents such as laminin-5,
is associated with a worse prognosis of the disease
and with resistance to targeted drugs like geﬁtinib
(Giannelli et al., 2003, 2004). Communication between
the hepatocyte and the ECM is mainly mediated by a
family of trasmembrane receptor proteins collectively
known as integrins (Hynes, 1992). These receptors
consist of an a- and a b-subunit, and exist in at least
24 different combinations, with different binding speci-
ﬁcities and signaling mechanisms (Schuppan and Ocker,
2003). The interaction of integrins with ECM compo-
nents (i.e., collagen, laminin and ﬁbronectin, among
others) regulates essential responses like cell adhesion,
migration, differentiation and survival (Hynes, 1992).
The intracellular domains of integrins lack an enzymatic
activity, and in order to signal they need to associate
with intracellular kinases such as focal adhesion kinase
(FAK) and integrin-linked kinase (ILK) (Hannigan
et al., 2005; Von Sengbusch et al., 2005). As occurs
with the composition of liver ECM, the normal
expression pattern of integrins is also altered early
during hepatocarcinogenesis. The resulting abnormal
combination of ECM ligands and integrin receptors has
been proposed to play a role in liver tumor development
and metastasis (Carloni et al., 2001; Nejjari et al., 2002;
Yang et al., 2003; Zhang et al., 2003). In particular,
overexpression of integrin b1 in human HCC cells has
been demonstrated to enhance cell proliferation, survial,
migratory capacity and resistance to chemotherapy
(Carloni et al., 2001; Zhang et al., 2002, 2003, 2004).
Similarly, induction of FAK gene expression has been
observed in human HCC, and elevated FAK levels seem
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to correlate with a more aggressive tumor behavior (Itoh
et al., 2004; Fujii et al., 2004). Interestingly, the
proﬁbrogenic growth factor TGF-b, which as mentioned
before participates in the EMT and induces migratory
capacity in liver tumor cells, can stimulate the expres-
sion of ILK and certain integrins, and also can promote
FAK tyrosine phosphorylation in human HCC cells
(Nejjari et al., 2002; Xu et al., 2003). Taken together
these observations suggest that inhibition of the
progression of liver ﬁbrosis and of ECM/tumor cell
interactions, could represent alternative therapeutic
strategies to prevent HCC development and metastasis.
Various approaches acting on different targets can be
envisioned. For example, interfering with TGF-b
activity could have pleiotropic beneﬁcial effects, and
different strategies using synthetic peptides, soluble
decoy receptors or adenovirus-mediated local expression
of dominant-negative TGF-b receptors, have been
attempted (Ezquerro et al., 2003; Pinzani et al., 2005).
Inhibition of downstream signaling from the integrin
receptors could be another possibility. The expression of
the integrin-associated kinase ILK is increased in
different types of tumors, and this kinase seems to
participate in the malignant progression (Hannigan
et al., 2005). These notions have prompted an active
search for small molecule ILK inhibitors, and several
compounds such as KP-SD-1, KP-392 and QLT0254,
have proved antitumor activity in xenograft models
(Hannigan et al., 2005; Yau et al., 2005). Although no
experiences have been reported in HCC cells or models,
liver tumors are likely to respond to ILK inihibitors,
given that increased ILK activity can be due to loss of
expression or inactivation of PTEN (Hannigan et al.,
2005), which are common events in HCC.
Clinical development of targeted therapies
Unlike conventional chemotherapy, ‘targeted agents’
aim to block the growth and spread of cancer by
interfering with speciﬁc molecules involved in tumor
growth and invasiveness. Consequently, they point
towards increased efﬁcacy and reduced toxicity. As it
has been discussed, targets can be aimed at with mAbs
that speciﬁcally bind to growth factors or growth-factor
receptors, or can be hit with small molecules acting as
signal-transduction inhibitors (Table 1). Among the
latter, earlier agents such as geﬁtinib and erlotinib aimed
at single targets (in this case EGFR), but more recently
other kinase inhibitors, including sorafenib (BAY 43-
9006) or SU11248, have multitarget properties.
Although HCC seems to stand on the rear in the clinical
research of targeted therapies, a number of targeted
therapies have already moved into clinical trials on the
HCC population (Table 2).
Table 1 Principal targeted agents under clinical research for the treatment of solid tumors
Name Target Current status
Small-molecule inhibitors
Geﬁtinib (Iressa) EGFR Approved for NSCLC
Erlotinib (Tarceva) EGFR Approved for NSCLC
Imatinib (Gleevec) bcr-abl, PDGF & c-kit Approved for CML and GIST
Sorafenib, BAY 43-9006 Raf kinase, VEGFR, PDGFR Approved for RCC
CI-1033 pan-erbB Clinical development
EKB-569 EGFR Clinical development
PKI-166 erbB1& erbB2 Clinical development
Lapatinib, GW572016 EGFR & erbB2 Clinical development
SU11248 VEGFR, PDGFR, Flt3, and c-kit Clinical development
ZD6474 VEGFR-2, EGFR Clinical development
SU5416 VEGFR-2, c-kit Clinical development
Vatalanib, PTK/ZK Multiple VEGFR Clinical development
CI-1040 MEK-1 and MEK-2 Clinical development
Lonafarnib Farnesyl transferase Clinical development
Tipifarnib Farnesyl transferase Clinical development
Monoclonal antibodies
Trastuzumab (Herceptin) Humanized anti-Her2 Ab Approved for Her-2-positive metastatic breast cancer
Cetuximab (Erbitux) Chimeric anti-EGFR Ab Approved for CRC in combination with irinotecan
Bevacizumab (Avastin) Humanized anti-VEGF Ab Approved for CRC in combination with 5-FU regimes
Panitumumab, ABX-EGF Humanized anti-EGFR Ab Clinical development
HuMV833 Humanized anti-VEGF Ab Clinical development
Others
Temsirolimus (CCI-779) mTOR Clinical development
AP23573 mTOR Clinical development
VX-680 Aurora kinase Clinical development
VEGF-Trap Fusion protein binding VEGF in
the circulation and tissues
CML: chronic myeloid leukemia; CRC: colorectal cancer; EGFR: epidermal growth factor receptor; 5-FU: 5-ﬂuoruracil; GIST: gastrointestinal
stromal tumor; NSCLC: non-small-cell lung cancer; PDGF: platelet-derived growth factor; PDGFR: platelet-derived growth factor receptor;
MEK: mitogen-activated protein kinase kinase; RCC: renal cell cancer; VEGFR: vascular endothelial growth factor receptor.
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Among targeted therapies sorafenib is the agent most
extensively studied (Strumberg et al., 2005). Sorafenib is
the ﬁrst oral multi-kinase inhibitor that targets serine/
threonine and receptor TKs in both the tumor cell and
tumor vasculature. In preclinical models, sorafenib has
been shown to target members of two classes of kinases
known to be involved in both tumor cell proliferation
and tumor angiogenesis, including Raf kinase, VEGFR-
2, VEGFR-3, PDGFR-b, c-kit, FLT-3 and ret. After
having achieved promising results in a phase II trial and
waiting for approval as an orphan drug for renal cell
carcinoma, an international, randomized, double-blind,
placebo-controlled trial is currently recruiting patients
with advanced HCC. Another phase III trial is
investigating if there is any advantage on adding
sorafenib to doxorubicin for the treatment of HCC
and a phase I trial is studying the safety of the
combination of sorafenib with bevacizumab, an anti-
angiogenic agent already approved for the treatment of
colorectal cancer. Bevacizumab itself is on phase II trials
either alone or combined with transarterial chemoem-
bolization, an appealing combination considering that
the therapeutic effect of the later could be quelled by
neoangiogenesis that would be inhibited by bevacizu-
mab.
Erlotinib, a receptor TK inhibitor with speciﬁcity for
the EGFR, already approved for the treatment of
NSCLC has very recently shown that warrants further
research in HCC patients. In a phase II trial, 32% of the
patients recruited were free of progression at 6 months
(Philip et al., 2005). Yet, 26% of patients needed a dose
reduction due to toxicity (mainly skin toxicity and
diarrhea) stressing that side effect may also be important
among cirrhotic patients with HCC. A phase I study is
currently evaluating the pharmacokinetics of erlotinib in
patients with liver dysfunction.
Other small molecules undergoing clinical research
include bortezomib, a proteasome inhibitor approved
for the treatment of multiple myeloma; lapatinib, an
ErbB-2 and EGFR TK inhibitor; and ispinesib that acts
by disrupting the function of kinesin spindle protein, a
cytoskeletal protein that is essential for cell proliferation.
However, targeted agents are not the only drugs
undergoing clinical development for the treatment of
HCC. Thymitaq is a novel, oral thymidylate synthase
inhibitor that showed promising result in a non-
controlled phase II trial (Stuart et al., 1999) but no
superiority to doxorubicin in a randomized trial in
Chinese patients with HCC. An intravenous formula-
tion is being tested in a pivotal, multinational, phase III
trial among patients with unresectable HCC comparing
Thymitaq to doxorubicin for which recruitment has
been completed.
DENSPM is a dysfunctional polyamine analog that
downregulates the synthetic enzymes of polyamine
metabolism and upregulates the catabolic enzyme,
rendering cells devoid of functional polyamines such
as putrescine, spermidine, and spermine that are
essential for cell growth and differentiation of both
normal and malignant cells (Wallace and Fraser, 2003).
DENSPM is now on a phase I/II trial to evaluate its
potential for the treatment of HCC.
Targeting drugs to liver cells can be achieved using a
series of phosphate and phosphonate prodrugs that
result in liver-targeted drug delivery following a
cytochrome P450-catalysed oxidative cleavage reaction
inside hepatocytes. MB07133 is a prodrug of cytarabine
that produces higher levels of the biologically active
form of PMEA and araC in the liver and lower levels in
the most toxicologically sensitive organs (Erion et al.,
2005) and is currently on a phase I/II trial in HCC
patients.
Table 2 Ongoing clinical trials in the USA involving new drugs speciﬁcally for the treatment of HCC (data were obtained from http://
www.cancer.gov/clinicaltrials)
Agent Target Phase Observations
Sorafenib Multiple tyrosine kinase inhibitor (VEGF, RAF) II/III Randomized (DOX+SOR vs DOX)
III Randomized (SOR vs placebo)
I SOR+ bevacizumab
Nolatrexed (Thymitaq) Thymidylate synthase inhibitor III Randomized (NOL vs DOX)
Megestrol Anti-estrogen III Randomized (megestrol vs placebo)
DENSPM Depletion of the cellular pool of polyamines I/II
MB07133 Antiproliferative (precursor of araC) I/II
PHY906 Potentiate antitumor effect of capecitabine I/II Herbal remedy
Arsenic trioxide Antineoplastic II
Bortezomib (Velcade) Proteasome inhibitor II Approved for multiple myeloma
I Patients with liver dysfunction
Thalidomide Antiangiogenic II In combination with epirubicin
Bevacizumab (Avastin) anti-VEGF mAb II
II TACE vs TACE+bevacizumab
I SOR+bevacizumab
Erlotinib (Tarceva) EGFR-tyrosine kinase inhibitor II
I Patients with liver dysfunction
AGI-PEG 20 Arginine depletion II
Thymalfasin (Zadaxin) Immunomodulator II TACE vs TACE+thymalfasin
Ispinesib, SB-715992 Disrupts kinesin spindle protein II
Lapatinib, GW572016 ErbB-2 and EGFR tyrosine kinase inhibitor II
DOX: doxorubicin; NOL: nolatrexed; SOR: sorafenib; TACE: transarterial chemotherapy.
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Pegylated arginine deiminase (ADI-PEG 20) deserves
a separate mention. It has been recently found that
human HCC cell lines require arginine for growth.
Arginine is not an essential amino acid for human adults
or infants as it can be synthesized from citrulline.
Therefore, selective elimination of arginine from the
circulation may be a means of treating patients with
HCC. Arginine deiminase, an arginine-degrading en-
zyme, is active against experimental HCC (Ensor et al.,
2002). ADI-PEG 20 partly overcomes the drawbacks of
a short half-life and strong antigenicity, and it has been
shown that a weekly injection of ADI-PEG 20
eliminates all detectable arginine from plasma (Izzo
et al., 2004). Outstanding results of this phase I/II trial
in which two out of 19 patients had a complete response,
and seven more had a partial response have encouraged
further clinical development.
Nevertheless, some issues should be born in mind
regarding the development of targeted therapies for
HCC. The failure of conventional antineoplastic che-
motherapy in the ﬁght against HCC is due both to
tumor cell resistance and to an altered pharmacody-
namics/pharmacokinetics in the setting of liver cirrhosis
(Morgan and McLean, 1995) that may enhance the side
effects of many ‘non-selective’ cytotoxic drugs. And this
may be the case also for new agents. In particular,
cutaneous side effects of kinase inhibitors may be very
distressing since they are chronic due to the long
duration of treatment and several studies have reported
a link between the antitumor efﬁcacy of EGFR
inhibitors and cutaneous side effects (Robert et al.,
2005). And it has been stressed that chronic liver disease
that usually underlies HCC may in fact enhance the
toxicity of agents such as erlotinib. On the other hand,
many small molecules seem to work better as adjuvants
to cytotoxic drugs than as single agents (antiangio-
genics, inhibitors of matrix metalloproteinases and anti-
EFGR antibodies) and this might obviously limit their
efﬁcacy against HCC.
Gene therapy and combined cell and gene therapy
Basic concepts
Gene therapy is based on the transfer of nucleic acid
sequences to tissues to promote the local synthesis of a
therapeutic protein or to block the expression of a
speciﬁc gene. The transferred can be the expression
cassette of a cDNA (or various expression cassettes of
several cDNAs), small interfering RNAs or antisense
sequences. To facilitate the entry of the genetic material
into cells a variety of molecular constructs, named gene
therapy vectors, are used. These can be divided into viral
and non-viral vectors, being the former preferred
because of their higher transduction efﬁciency. Viral
vectors are generated by eliminating some, or all, viral
genes leaving intact those sequences required in cis for
packaging the vector genome into the viral capsid or for
integration of vector DNA into the host genome. The
deleted sequences can be replaced by the therapeutic
gene(s) thus enabling the infected cell to express the
transgene. The efﬁcacy of gene therapy depends not only
on the selection of the appropriate therapeutic gene(s),
but also on efﬁcient cell transduction (penetration and
function of the transgene inside the target cell), on the
duration of transgene expression in the treated tissue, on
the toxicity of the vector or transgene and on the activity
of regulatory elements used to control gene expression.
Each viral vector system is characterized by an
inherent set of properties that affect its suitability for
speciﬁc gene therapy applications. Thus, the choice of
the vector is a critical issue since tissue tropism, duration
of gene expression, number of cells that are transduced,
fate of transgene (episomal vs integration into the cell
genome) and toxicity differ among the various types of
vectors used. For example, lentiviruses and other
retroviuses as well as adeno-associated viruses (AAV)
promote the integration of the transgene into the
genome, while adenoviral vectors permit the transgene
to remain in an episomal form. Integrating vectors and
helper-dependent (HD) adenoviral vectors allow long-
term expression of the transgene, while ﬁrst-generation
adenoviruses only enable short duration (5–8 days) of
gene expression. Toxicity also varies among vectors
being considerable less for HD adenoviruses than for
ﬁrst-generation adenoviral vectors (O’Neal et al., 2000).
The risk of insertional mutagenesis should be considered
for AAV, lentiviruses and other retroviruses and is less a
concern for adenoviral vectors. Also cloning capacity,
immunogenicity, as well as the feasibility and cost of
large-scale production are important issues for the
selection of the vector.
Gene therapy of cancer can be combined with cell
therapy for two main purposes: (a) to potentiate
antitumor immune responses or (b) to populate the
tumor vasculature with engineered cells able to secrete a
therapeutic compound inside the tumor mass (Rumpold
et al., 2004). Thus, dendritic cells (DCs) engineered ex
vivo with gene therapy vectors encoding immunostimu-
lating cytokines can be pulsed with tumor lysates and
injected into the lymph nodes to activate antitumor
immunity. In another application endothelium progeni-
tor cells transduced ex vivo with lentiviral vectors
encoding therapeutic genes under the control of an
inducible promoter are given intravenously for recruite-
ment by tumors with high angiogenic activity (as is the
case of HCC). This would allow the expression of the
transgene inside the tumor nodules when the activator
of the promoter is administered to the patient.
Strategies for hepatocellular carcinoma gene therapy
Gene therapy is a highly plastic procedure that can be
used in many different ways to combat cancer. The aim
of the intervention could be: (a) to induce a direct lysis
of the tumor cells, (b) to stimulate antitumor immunity,
(c) to block tumor growth by changing the biological
conditions of the tumor environment (d) to combine
various of these effects. As a result of difﬁculties to
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transduce the tumor by intravenous route, direct
injection of the vector into the tumor nodule, or in the
peritumoral tissue, using echographic guidance, is the
preferred way to achieve an efﬁcient transduction in the
patients with liver cancer.
Tumor-suppressor genes
It has been shown that transferring wild-type p53 gene
to p53-negative HCC cells inhibits tumor growth and
increases the sensitivity to chemotherapy (Xu et al.,
1996). However, only a modest therapeutic effect was
obtained in clinical trials using adenovirus-mediated
gene transfer of p53 (Warren and Kirn, 2002). The
limited efﬁcacy of p53 gene supplementation reﬂects the
inability to transduce efﬁciently all the tumor cells with
vectors presently available. To overcome this obstacle, a
number of procedures have been proposed including the
use of vectors with the ability to replicate selectively in
the tumor cells and the utilization of systems enabling
the transgenic product to diffuse and penetrate neigh-
boring cells (Qian et al., 2002). One example of the latter
strategy is the fusion of p53 to VP22, a protein from
herpes simplex virus type 1 (HSV-1) with the remarkable
property of being transported through cell boundaries
(Zender et al., 2002).
Suicide genes: therapy and imaging
Genes encoding for enzymes that convert an innocuous
prodrug to a toxic compound are known as suicide
genes. Thymidine kinase (tk) from HSV-1 is the best-
characterized prodrug activation enzyme (Fillat et al.,
2003). It converts ganciclovir (a well-tolerated antiviral
drug) into a toxic phosphorylated compound that
inhibits both nuclear and mitochondrial DNA synthesis
leading to cell death (Fillat et al., 2003; Herraiz et al.,
2003). This strategy allows concentrating the action of
the toxic metabolite in the tumoral tissue avoiding
systemic toxicity. An interesting property of suicide
genes is the so-called bystander effect that potentiates
antitumor activity by the diffusion of the activated
prodrug to non-transduced neighboring cells (Mesnil
and Yamasaki, 2000). The bystander effect may also
derive from the stimulation of the antitumoral immune
response as a result of necrosis and apoptosis in the
tumor (Kianmanesh et al., 1997). A synergistic anti-
tumoral effect was observed when co-transferring tk and
genes of immunostimulatory cytokines (Drozdzik et al.,
2000).
In a recent trial (Penuelas et al., 2005) a ﬁrst-
generation adenovirus encoding HSV-tk under the
control of CMV promoter (AdCMVtk) was used to
treat 7 patients with HCC by intratumoral administra-
tion of the vector in a dose-escalation fashion from
2 1010 to 2 1012 v.p. in consecutive patients. Contrary
to patients treated with lower doses, those who received
1012 v.p. or more (n¼ 4) showed estabilization of the
treated tumor and in two of them wide areas of necrosis
were apparent in the computed tomography scan
performed at day 30 after therapy. Tolerance was good
and no signiﬁcant side effects were apparent. In this
trial, positron emission tomography (PET) imaging was
employed to monitor transgene expression using a
labeled substrate of HSV-tk ([18F]FHBG). With this
methodology strong retention of the label was found in
the treated tumor nodules in all patients that received
1012 v.p or more but not in those given lower vector
doses (Figure 2). Interestingly the surrounding non-
tumoral cirrhotic tissue was completely spared from
transduction in all cases. This study demonstrated that
Figure 2 Imaging of adenovirus-mediated transgene (thymidine kinase) expression in hepatocellular carcinoma (HCC) tumor nodule
using positron emission tomography (PET) (a) and combined PET plus Computed Tomography (CT) (b) PET imaging of a HCC
tumor nodule that received an intratumor injection of 1012 viral particles of an adenovirus encoding thymidin kinase (HSV-tk) given 2
days before the study. The upper three panels correspond to PET images and the lower three panel to combination PET-CT. PET
imaging was performed 60min after administration of [18F]FHBG (a 18-ﬂuorine-labeled penciclovir ananlogue which is a substrate for
HSV-tk). The strong retention of the label can be appretiated in the transaxial sections of PET (a) and PET–CT (b) shown in the ﬁgure.
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human HCC are easily infected with adenoviral vectors
and it also showed that a second dose of the vector fails
to transduce the tumor possibly as result of the
development of neutralizing antiadenoviral antibodies.
Antitumoral effect against HCC and metastatic liver
cancer was observed using other prodrug-activating
enzymes including cytosine deaminase that turns anti-
fungal 5-ﬂuocytosine into 5-ﬂuoruracil (Ohwada et al.,
1996; Humphreys et al., 2001), Escherichia coli purine
nucleoside phosphorylase that converts ﬂudarabine into
a diffusible toxic compound (Mohr et al., 2000) and
bacterial nitroreductase which converts CB1954 (5-
(azidrin-1-yl)-2,4-dinitrobenzamide) to a short lived,
very toxic DNA crosslinking compound. Recently, a
clinical trial in patients with primary and metastatic liver
cancer using intratumoral injection of escalating doses
(1085 1011 v.p.) of a ﬁrst adenovirus-encoding nitror-
eductase showed good tolerance of the procedure and a
dose-related expression of the transgene in the biopsy of
the treated tumor (Palmer et al., 2004).
Oncolytic virotherapy
This strategy is based on the use of viruses that replicate
and kill preferentially tumor cells. These cells then
become cell factories of new viral particles that infect
surrounding tumor cells. Adenoviruses have been
extensively used for the production of oncolytic agents.
The ﬁrst of this kind of virus (named dl1520 or ONYX-
015) is based on the deletion of the E1B 55K viral gene,
which makes its replication dependent on the defect of
the p53 pathway in the infected cells (McCormick,
2003). In clinical trials, ONYX-015 has proved to be
safe after intratumoral injection in humans (Kirn, 2001).
A pilot clinical trial of intratumoral injection of the virus
for the treatment of primary and secondary tumors
revealed that the treatment was well tolerated and some
clinical responses were observed (Habib et al., 2001).
However, a further study in which repeated intratumor-
al injections of this replication-selective adenovirus were
given to patients with HCC failed to show clinically
relevant efﬁcacy (Habib et al., 2002) presumably because
of generation of neutralizing antibodies. In hepatobili-
ary tumors, biological responses were observed, but
o10% of the patients showed partial responses
(Makower et al., 2003).
Another approach to restrict adenovirus replication in
tumor cells is based on the transcriptional control of
viral genes that are essential for replication (e.g. E1)
using tumor-speciﬁc promoters such as AFP, the human
telomerase reverse transcriptase or E2F promoters
(Huang et al., 2003a; Jakubczak et al., 2003; Wirth
et al., 2003; Irving et al., 2004; Zou et al., 2004). In
addition to adenovirus, other viruses, including the
rRp450 mutant of HSV-1 or the vesicular stomatitis
virus, have been used as selective oncolytic agents in
HCC (Pawlik et al., 2000; Ebert et al., 2003; Huang
et al., 2003b).
The oncolytic viruses can also be used as potential
vectors to convey therapeutic genes to tumor cells.
Oncolytic adenovirus encoding granulocyte-macro-
phage colony-stimulating factor (GM-CSF), TRAIL
or second mitochondria-derived activator of caspases
have been shown to exert a potent antitumor effect in
experimental HCC (Bristol et al., 2003; Pei et al., 2004).
Similarly, IL-12 has been incorporated into oncolytic
HSV offering effective control of primary hepatic
tumors and protection against microscopic residual
disease after resection (Jarnagin et al., 2003).
Antiangiogenic gene therapy
Since HCC is a highly vascularized tumor, an attractive
therapeutic strategy is based on gene transfer of
antiangiogenic factors to the tumor or peritumoral
tissue using long-term expression vectors. This approach
would allow obtaining high concentration of the
antiangiogenic molecule at the tumor site with reduced
risk of systemic toxicity. Although soluble VEGF
receptors (Goldman et al., 1998; Raskopf et al., 2005)
and other antiangiogenic molecules, such as Tie2
receptor, angiostatin, endostatin and pigment epithe-
lium-derived factor (PEDF) have shown antitumor
activity in animal models of HCC (Lin et al., 1998;
Griscelli et al., 1998; Schmitz et al., 2002; Folkman,
2003; Wang et al., 2003), clinical trials have not been
initiated so far.
Immuno-gene therapy
Tumors express neoantigens that could elicit protective
immunity but antitumor immune responses are in
general weak or ineffective due to low expression of
MHC molecules (Algarra et al., 2000), production of
immunosuppressive factors (TGF-b, IL-10, VEGF or
IL-8) (Ranges et al., 1987), induction of CD4þ
CD25þ regulatory T cells (Treg) (Antony and Restifo,
2005) or expression of Fas ligand by neoplastic cells
resulting in apoptosis of tumor-inﬁltrating T cells
(Strand et al., 1996). On the other side tumour cells
can exploit host-derived cytokines to increase resistance
to apoptosis and to stimulate growth and dissemination
(Dranoff, 2004). Gene therapy can be used to overcome
these barriers and to promote antitumor responses.
Cytokines (such as IL-2, IL-12, IL-15, TNF-a and IFN-
g) generated during the immune response, in inﬂamma-
tion and in infection, can restrict tumor growth and it
has been shown that their systemic administration could
elicit antitumor effects (Dranoff, 2004). However, the
severe toxicity associated with these treatments limits
their application.
Gene transfer of immunostimulatory cytokines to the
neoplastic cells increases local levels of the cytokine
without undue elevation of serum concentration thus
widening the therapeutic window and reducing toxicity.
A variety of immunostimulatory cytokines, chemokines
or co-stimulatory molecules (IL-2, IL-7; IL-12, IL-15,
IL-18, IL-21, IL-23, IFN-g, TNF-a, GM-CSF, IP-10,
CD40-L and B7.1) have been employed with efﬁcacy in
gene therapy of diverse tumor models (Prieto et al.,
2004). Interleukin-12 is a particularly potent antitumor
cytokine which induces a TH1 type of response
(Trinchieri, 1998; Mazzolini et al., 2003a, b), activates
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cytotoxic T lymphocytes and natural killer cells and
displays robust antiangiogenic activities (Sgadari et al.,
1996; Mazzolini et al., 2000; Barajas et al., 2001).
Interestingly, combined gene transfer of IL-12 and the
chemokine IP-10, or of IL-12 and the chemokine
MIP3a, or of IL-12 and the co-stimulatory molecule
B7.1 results in synergic antitumoral effect (Narvaiza
et al., 2000; Putzer et al., 2001; Mazzolini et al.,
2003a, b). In experimental HCC in rats gene therapy
with either CD40-L (Schmitz et al., 2001) or IL-12
(Barajas et al., 2001) has been reported to induce tumor
eradication without signiﬁcant toxicity.
Of all immunogene therapeutic strategies used to treat
experimental cancer models only IL-12 gene therapy has
been transferred to the clinic to treat liver cancer
(Sangro et al., 2004). The clinical trial was performed
in patients with liver tumors (either primary or
secondary to colorectal and pancreatic carcinomas) that
received 1–3 intratumoral injections of a ﬁrst-generation
adenoviral vector encoding human IL-12 genes. The
treatment was without any signiﬁcant side effects and in
fact the maximal tolerated dose was not reached.
However, the antitumor effect was weak with only one
partial response in a patient with HCC. In general
patients with HCC had a better outcome than other
histological groups in this trial. These modest antitumor
effects were probably due to the low and short-lived
expression of the transgene when using ﬁrst-generation
adenovirus, and to the inability to repeat tumor
transduction with a second vector injection due to
production of neutralizing antiadenoviral antibodies
after the ﬁrst administration of the adenovirus.
Engineered dendritic cells
Genetic manipulation of DCs is a promising alternative
to activate antitumor immunity. Dendritic cells trans-
duced with speciﬁc antigens together with genes encod-
ing cytokines or co-stimulatory molecules exhibit
augmented antigen-presenting function (Tirapu et al.,
2002) and it has been shown that intratumoral injection
of DC engineered to produce IL-12 can induce tumor
regression in animal models of digestive cancer (Melero
et al., 1999). Moreover, the antitumor efﬁcacy of this
strategy can be reinforced by administration of the anti-
CD137 mAb which is endowed with potent immunos-
timulatory activity (Tirapu et al., 2004). On the basis of
these preclinical ﬁndings a clinical trial was performed in
patients with primary or metastatic liver cancer using
intratumoral injections of monocyte-derived DC trans-
duced with ﬁrst-generation adenoviral vectors encoding
IL-12 (Mazzolini et al., 2005). The patients received up
to three equal doses of cells (doses were escalated from
10 to 50 millions of cells in three cohorts of patients) at
21 days intervals. The expectation was that the modiﬁed
DCs would take up tumor antigens and migrate to
lymph nodes to activate a speciﬁc TH1 antitumoral
response by locally secreting IL-12. However, although
the procedure was well tolerated, the elicited antitumor
effect was weak. It was found that the tumor, by
secreting IL-8, sequesters the injected DC and prevents
their migration to regional lymph nodes rendering the
therapy inefﬁcient (Feijoo et al., 2005).
Clinical trials are needed to test whether autologous
mature DC (genetically engineered or not) pulsed with
tumor lysate or tumor RNA (obtained from the surgical
specimen) and injected inside lymph nodes (not within
the tumor mass) could efﬁciently stimulate speciﬁc
antitumor responses in HCC patients. This therapy
might be useful to eliminate minimal residual disease
after surgery rather than to control growth of advanced
cancer.
Perspectives of hepatocellular carcinoma gene therapy
Until present, ﬁrst-generation adenoviruses are the
vectors most frequently used in clinical trials of cancer.
With this type of vectors, HCC tumor transduction is
good but the expression of the transgene is short lived
and repeated transduction of the tumor is not feasible
due to neutralizing antiadenoviral antibodies. The short
duration of transgene expression seems to be the cause
of the limited therapeutic effect. From the accumulated
experience it seems that long-term expression vectors
should be used to enhance effectiveness and appropriate
promoters should be developed to ensure prolonged and
regulable expression of the therapeutic transgene and
vector technology should be improved to generate
sophisticated vectors at high titers for clinical use.
With the progress in the knowledge of tumor biology
novel targets have been identiﬁed. This creates new
opportunities for gene therapy which can rely not only
on immuno-gene strategies, oncolytic virotherapy or
suicide genes but also on the expression inside the
proper tumor mass of humanized mAbs or decoy
molecules directed to block those factors that are crucial
for tumor progression such as growth factors, growth
factors receptors, metalloproteases or integrins. In other
words, gene therapy can be used to generate within the
proper tumor mass those substances that can disrupt the
biologic microenvironment that the tumor needs to
grow. The recruitment of circulating progenitor cells by
the tumor can be exploited by genetic engineering of
these cells which can then be administered to the patient
as vehicle of therapeutic genes. This combination of cell
and gene therapy represents an attractive strategy to
target all metastatic tumor lesions.
Radiotherapy
Once neglected because of the low tolerance of the liver
to irradiation, radiotherapy has emerged as a promising
tool for the treatment of HCC as new technologies allow
the selective delivery of tumoricidal doses of radiation to
liver tumors (Geschwind et al., 2004). External con-
formal radiation therapy using linear accelerator (Park
et al., 2005) or proton beam (Kawashima et al., 2005)
result in response rates above 60% with doses higher
than 50Gy showing that HCC is a radiosensitive
neoplasm. Selective radiation can also be accomplished
with the use of carriers, and this is particularly valuable
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for multinodular tumors (Table 1). Selective Internal
Radiation Therapy (SIRT) can be achieved using 90Y-
loaded microspheres made of either resin (SIR-Spher-
ess, Figure 3) or glass (Theraspheress). They can be
delivered as selectively as possible (from subsegmental
to whole liver), and provides millions of scattered point
sources of radioactivity, as opposed to the uniform ﬁelds
of external beam radiotherapy. This difference in ﬁeld
properties for a given measure of radiation-absorbed
dose results in different biological effects (Kennedy
et al., 2004). Results from non-randomized trials or
retrospective series show that tumor control can be
achieved in a signiﬁcant proportion of patients with
good tolerance and suggest that survival may be similar
to that obtained with transcatheter arterial embolization
(Liu et al., 2004; Kulik et al., 2005; Goin et al., 2005a, b).
Yet, large randomized trials should be conducted to
compare SIRT vs TACE for the treatment of advanced
HCC. SIRT also merits clinical investigation as a
method to prevent tumor progression while on the
waiting list for liver transplantation. Lipiodol can also
be used as a carrier of radionuclides including 131I
(Raoul et al., 1997) and 188Re (Sundram et al., 2004), the
latter having several assets from the radioprotection
perspective. Yet, there is little evidence that therapy is
indeed selective and toxicity may be a signiﬁcant
problem, particularly for patients with Child-B func-
tional status (Lambert et al., 2005).
Immunotherapy
A thorough review of new immunological therapies for
HCC is beyond the scope of this paper. However, a
number of strategies aiming at stimulating immunity
against liver tumors can be outlined. High-dose inter-
feron-alpha (50MU/m2, tiw) has signiﬁcantly prolonged
survival of HCC patients (Lai et al., 1993) suggesting
that it might be worth stimulating the immune system of
patients with HCC if the immune stimulating agent has
a good toxic proﬁle. Interleukin 2 was also able to
produce objective remissions among HCC patients
(Palmieri et al., 2002). But then again, toxicity limits
widespread application of IL-2 to cirrhotics. Other
cytokines such as IL-12, TNF-a or TRAIL have still not
been tested for human liver cancer but there are
preclinical data in rodents that suggest a potential
interest.
Monoclonal antibodies can be designed that bind
molecules on the surface of lymphocytes or antigen-
presenting cells and provide activating signals. Alter-
natively, they can be used to block the action of surface
receptors that normally downregulate immune re-
sponses. In combined regimes of immunotherapy, these
mAbs are expected to improve therapeutic immuniza-
tions against tumors as it has been observed in
preclinical models. Anti-CTLA-4mAb that block the
inhibitory function of CTLA-4 on T cells have already
started clinical trials against prostate cancer (Kuhns
et al., 2000), and the preclinical effects described for
anti-CD40, anti-CD137 (4-1BB), anti-CD102 (intercel-
lular adhesion molecule-2), and Treg-depleting mAbs
should lead to their prompt clinical development.
(Murillo et al., 2003).
Dendritic cells, the most potent antigen-presenting
cells in vivo, can be used to elicit antitumor immunity. In
a recent trial autologous DCs derived from peripheral
monocytes and pulsed with tumor lysates were injected
intravenously in 31 patients with advanced HCC. A
partial response was observed in 13% of cases and
survival was better in those that received boost
vaccinations after the initial pulsed therapy than in
those treated by pulsed therapy alone (Lee et al., 2005).
Adoptive T-cell therapy consists in rising and infusing
in vitro cultured T cells that mediate speciﬁc destruction
of tumor cells. The main hurdle in its application is the
difﬁculty to obtain such T-cell cultures against epithelial
tumors. The use of dendritic cells to prime T-cell
cultures in vitro can be very helpful for this purpose.
In a randomized clinical trial, Takayama et al. (2000)
showed that adoptive immunotherapy consisting of
autologous lymphocytes activated in vitro and adminis-
tered to patients who had received curative resection for
HCC is a safe therapeutic approach that reduces post-
surgical recurrence at 3 (48 vs 33%) and 5 years (38 vs
22%). New techniques of selection and culture of
tumor-speciﬁc cells as well as combination therapy with
tumor vaccination protocols are expected to improve the
outcome.
Corollary
Non-resectable cancer can be treated either by directly
targeting the tumor cells or by increasing the defense of
Figure 3 Selective internal radiation therapy (SIRT) for hepato-
cellular carcinoma. The left panel shows the appearance of a large
liver tumor (white arrows) before (a) and 3 months after the
injection of microspheres loaded with Yttrium-90 into the common
hepatic artery (b). The right panel shows the size and lodgement of
these microspheres relative to the large (150–300mm) spheres
commonly used for transarterial embolization (black arrows) (c).
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the host against tumor growth. Direct attack to tumor
cells can be executed using non-speciﬁc cytotoxic
therapies such as conventional chemotherapy or radio-
therapy or by targeted therapy with substances able to
block speciﬁc biological processes conferring tumor cells
the ability to grow inappropriately, to resist apoptosis,
to invade and to metastatize. Host defense against
cancer can be boosted by vaccination with tumor
antigens, inhibition of Treg or adoptive immunization.
Host resistance to neoplastic growth can also be
enhanced by disrupting the tumor biologic microenvir-
onment blocking signals emanating from the neoplastic
cells that promote angiogenesis and the formation of
tumor stroma.
Hepatocellular carcinoma is highly resistant to con-
ventional chemotherapy. This tumor is also a poorly
immunogenic neoplasm although immunotherapy may
be used to prevent recurrences after surgical resection or
percutaneous ablation. On the other hand HCC is rarely
amenable to radiotherapy because of multinodularity
and underlying liver disease although SIRT and external
conformal radiation may have a role in speciﬁc
indications. All these features make advanced HCC a
very difﬁcult tumor to treat. However, the impressive
advances in the knowledge of tumor biology taken place
during the last years and the remarkable success of
targeted therapy in other tumors (either alone or in
combination with cytostatics) has opened promising
avenues for HCC therapy. In HCC multiple molecular
alterations ensure the incessant growth of the neoplastic
cells. Since the blockade of a speciﬁc target can be
overcome by other molecular abnormalities, it is likely
that HCC could easily develop resistance to compounds
that hit a single molecule. Drugs designed to block
different growth-promoting pathways (promiscuous
drugs such as multiple kinase inhibitors) or combination
of different targeted therapies might however attain
success in the control of liver cancer. As shown in the
case of breast cancer, targeted therapy against molecules
conveying growth-promoting signals may render HCC
sensitive to speciﬁc chemotherapeutic protocols. In the
future methods to analyse the molecular signature of
each HCC might make possible to select the appropriate
combination of targeted therapies that should be used in
the particular patient. However toxic side effects of drug
combinations will be a risk specially in patients with
underlying liver cirrhosis and/or poor liver function.
Gene therapy is still at its infancy. Transduction of
the neoplasm with viral vectors leads to expression of
the transgene within the tumor mass enabling a high
concentration of the therapeutic substance inside the
tumor with low systemic levels thus increasing the
therapeutic window. Although, until present, the use of
ﬁrst-generation viral vectors did not achieve clinical
efﬁcacy, the lessons from pioneer clinical trials, the
utilization of PET for imaging of gene expression and
the development of new vectors enabling long duration
and regulatable transgene expression, make gene ther-
apy a promising approach to treat HCC.
Cell therapy represents an additional promise for the
future of HCC therapy. The possibility of isolating,
culturing and genetically engineering progenitor cells
that are recruited by the tumor after their intravenous
injection affords the possibility to direct the expression
of therapeutic molecules to both the primary and
metastatic tumor lesions.
To conclude, although at present the prognosis of
advanced HCC is dismal, new horizons with the promise
of better times are now at sight.
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